Compare Amgen, Inc. (AMGN) vs e l f Beauty Inc (ELF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs e l f Beauty Inc — how do they compare? Amgen, Inc. trades at $356.69 (market cap $196.12B), while e l f Beauty Inc trades at $75.55 (market cap $4.52B). The key difference: Amgen, Inc. is far larger — about 43.4× e l f Beauty Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while e l f Beauty Inc pays none. Which is the better fit depends on your goals.
| AMGN | ELF | |
|---|---|---|
Market Cap | $196.12B | $4.52B |
Sector | Health | Technology |
52-Week High | $388.16 | $146.67 |
52-Week Low | $271.18 | $49.57 |
Enterprise Value | $241.41B | $5.15B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
ELF trades at $76.75, up 1.31% with bullish technical signals and strong earnings beats. The stock shows robust revenue growth and high gross margins, though valuation multiples appear elevated. Recent news highlights brand expansion and market share gains, with analyst sentiment mixed but leaning positive.
Outlook remains optimistic due to consistent earnings outperformance and strategic initiatives, but risks include high P/E ratio, competitive pressures, and sensitivity to tariffs. Upside potential exists if growth targets are met, yet investors should weigh valuation concerns against growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About e l f Beauty Inc
e.l.f. Beauty is a leading cosmetics company offering high-quality, 100% vegan, and cruelty-free products. It is known for its affordable and prestige-quality makeup and skincare items for a diverse global audience.
Read more on ELF →
